Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Transplant Proc ; 46(1): 278-80, 2014.
Article in English | MEDLINE | ID: mdl-24507067

ABSTRACT

Intravenous immunoglobulin (IVIg) is a blood product with immunomodulating properties that have been widely applied in the management of renal transplant recipients. In general, IVIg has been considered a relatively safe therapy, with most adverse events being mild and transient. Although rare, a serious and well-recognized complication of IVIg is large-vessel thrombotic events, which are thought to be related to hyperviscosity. We describe here two cases in which there was a temporal relationships between the administration of IVIg, an acute decline in allograft function, and the histologic finding of de novo thrombotic microangiopathy (TMA). In both cases, IVIg had been administered to facilitate immunosuppressive dose reduction in the context of BK nephropathy. We believe this is the first report of TMA associated with IVIg administration in renal allograft recipients.


Subject(s)
Glomerulonephritis, IGA/complications , Immunoglobulins, Intravenous/adverse effects , Kidney Transplantation , Polyomavirus Infections/complications , Renal Insufficiency/surgery , Thrombotic Microangiopathies/chemically induced , Allografts , BK Virus , Glomerulonephritis, IGA/surgery , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunosuppression Therapy/adverse effects , Male , Middle Aged , Thrombosis
3.
Eur J Echocardiogr ; 10(3): 456-8, 2009 May.
Article in English | MEDLINE | ID: mdl-19174445

ABSTRACT

Although post-mortem studies would suggest that cardiac metastases occur frequently, many of these metastases remain clinically silent. However, symptomatic lesions may also remain unrecognized due to overshadowing by other symptoms of the primary malignancy. Patients undergoing treatment for cancer are not routinely screened using echocardiography, unless their chemotherapeutic regimen includes cardiotoxic agents. The current era of research and development of targeted biological agents (such as trastuzumab and epidermal growth factor receptor inhibitors) for cancer may lead to prolonged survival of oncology patients. In future, metastases that were once rare may become increasingly recognized as these new treatments augment the natural history of the disease. There have been several case reports of small, asymptomatic left ventricular metastases, but clinically significant ventricular metastases are very rare. There are no reports in the current literature of a symptomatic ventricular metastasis, occurring in the absence of other metastatic disease. We report an unusual case of a large solitary ventricular metastasis, leading to left ventricular outflow tract obstruction and haemodynamic compromise. Echocardiographic imaging led to the diagnosis of a recurrence of soft-tissue fibrosarcoma 9 years after original resection.


Subject(s)
Fibrosarcoma/secondary , Heart Neoplasms/secondary , Soft Tissue Neoplasms/secondary , Aged , Dyspnea/etiology , Echocardiography , Fatal Outcome , Fibrosarcoma/surgery , Heart Neoplasms/diagnostic imaging , Heart Neoplasms/surgery , Heart Ventricles/diagnostic imaging , Heart Ventricles/pathology , Humans , Male , Soft Tissue Neoplasms/diagnostic imaging , Soft Tissue Neoplasms/surgery , Ventricular Outflow Obstruction/diagnostic imaging , Ventricular Outflow Obstruction/etiology
4.
Int J Gynecol Cancer ; 13(3): 371-5, 2003.
Article in English | MEDLINE | ID: mdl-12801272

ABSTRACT

Mullerian adenosarcoma is a neoplasm composed of benign mullerian epithelium and a sarcomatous stroma. This tumor classically occurs in the endometrium of postmenopausal women and less frequently in the extrauterine genital tract. Rare cases of extragenital adenosarcoma have been reported. We present the case of a 23-year-old female who presented with an extragenital adenosarcoma arising in an endometriotic cyst in the pouch of Douglas. The patient was treated with local excision, chemotherapy and radiotherapy. At 2 years follow-up she was disease-free. The literature on extragenital adenosarcoma is reviewed. These tumors are clinically more aggressive than their uterine counterparts. Surgical excision is the initial treatment modality for these patients. Little information is available regarding the efficacy of adjuvant chemotherapy or radiotherapy. This is an area that requires further study.


Subject(s)
Adenosarcoma/pathology , Douglas' Pouch , Mixed Tumor, Mullerian/pathology , Peritoneal Neoplasms/pathology , Adenosarcoma/etiology , Adenosarcoma/surgery , Adult , Cysts/complications , Female , Gynecologic Surgical Procedures , Humans , Mixed Tumor, Mullerian/etiology , Mixed Tumor, Mullerian/surgery , Peritoneal Neoplasms/etiology , Peritoneal Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...